Peter O'Donnell

With the literal toss of a coin officially sending the EMA to Amsterdam post-Brexit, it's worth reflecting on what might have been if the decision went differently.

The decision of where to move the EMA was determined by a coin toss.

The operational subject of how the centralized authorization procedure is going to work when the UK is no longer part of the European Union is being discussed.

In this blog by Peter O'Donnell, the EU provides a report on the progress its made within the pediatric medicines regulation.

As concerns grow about the slow progress of advanced therapies, drug developers are pushing for action from European authorities.

Tensions mount across the European pharmaceutical scene over the fate of the EMA with just weeks before the final decision is going to be made on where it will be moved to.

New safety review of epilespy treatment puts spotlight on issues such as communication between regulators and prescribers.

The EMA isn't mincing its words about the challenge it faces with the relocation that will be forced on it by Brexit. It has been stated that "the future of public health in Europe is at stake" and this decision will make or break it.

Gaps in the good manufacturing practice controls on medicines for clinical trials are targeted in new rules from the EU.

This article outlines the EMA's response from a previous blog by Peter O'Donnell regarding the potential of Milan, Italy as the EMA relocation.

What cannot have escaped the attention of any impartial observer is that Milan is one of the leading contenders to host the EMA and that Tajani and Rasi are both Italian. The EMA relocation is a hot topic without any bias towards Milan.

The European Health Data Network (EHDN) initiative kicks off-a challenging and resource-intensive effort designed to harmonize data analysis and conversion amid the push toward outcomes-focused healthcare in Europe.